These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 22720323)

  • 41. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
    Galvis C; Colmenares A; Cabrales L; Ibatá L; Marulanda J; Ovalle O; Puello D; Rojas C; Africano M; Ballesteros A; Posso H
    Pediatr Pulmonol; 2022 Oct; 57(10):2420-2427. PubMed ID: 35791790
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
    Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
    South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
    Fenton C; Scott LJ; Plosker GL
    Paediatr Drugs; 2004; 6(3):177-97. PubMed ID: 15170364
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Respiratory syncytial virus infections in infants and children with congenital heart disease: update on the evidence of prevention with palivizumab.
    Resch B; Michel-Behnke I
    Curr Opin Cardiol; 2013 Mar; 28(2):85-91. PubMed ID: 23337892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Respiratory Syncytial Virus Bronchiolitis in Children.
    Smith DK; Seales S; Budzik C
    Am Fam Physician; 2017 Jan; 95(2):94-99. PubMed ID: 28084708
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regional impact of prophylaxis with the monoclonal antibody palivizumab on hospitalisations for respiratory syncytial virus in infants.
    Duppenthaler A; Gorgievski-Hrisoho M; Aebi C
    Swiss Med Wkly; 2001 Mar; 131(11-12):146-51. PubMed ID: 11416887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monoclonal Antibody Treatment of RSV Bronchiolitis in Young Infants: A Randomized Trial.
    Alansari K; Toaimah FH; Almatar DH; El Tatawy LA; Davidson BL; Qusad MIM
    Pediatrics; 2019 Mar; 143(3):. PubMed ID: 30760509
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prevention and prophylaxis of respiratory syncytial virus in pediatric cardiology: a UK perspective.
    Tulloh RM; Bury S
    Future Cardiol; 2014 Mar; 10(2):235-42. PubMed ID: 24762251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.
    Robinson KA; Odelola OA; Saldanha I; McKoy N
    Cochrane Database Syst Rev; 2010 Feb; (2):CD007743. PubMed ID: 20166098
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
    Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
    Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
    Acero-Bedoya S; Wozniak PS; Sánchez PJ; Ramilo O; Mejias A
    Am J Perinatol; 2019 Jul; 36(S 02):S63-S67. PubMed ID: 31238362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
    Rocca A; Biagi C; Scarpini S; Dondi A; Vandini S; Pierantoni L; Lanari M
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease.
    Feltes TF; Cabalka AK; Meissner HC; Piazza FM; Carlin DA; Top FH; Connor EM; Sondheimer HM;
    J Pediatr; 2003 Oct; 143(4):532-40. PubMed ID: 14571236
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
    Kua KP; Lee SWH
    Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
    Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
    Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.